MilliporeSigma
HomeWebinarsOrganoids in Immuno-Oncology

Organoids in Immuno-Oncology



WEBINAR

This webinar explaines the importance of 3D cell culture models such as organoids in understanding cancer biology and their role in studying the interactions between cancer cells and the immune system. Additionally, it explores the potential applications and benefits of organoids in Immuno-Oncology and anti-cancer therapeutics.

What does it cover?
Immuno-Oncology is an emerging field that seeks to enhance the body's immune response against cancer. Traditional 2D cell cultures have limitations to replicate the tumor microenvironment. 3D models such as organoids, enables us to have more physiologically relevant and accurate representation of cancer biology that can investigate the interaction between cancer cells and the immune system.

What will you learn?

  • Why 3D cell culture models like organoids are critical for physiologically relevant cancer biology
  • How organoids can be used to investigate interactions between cancer cells and the immune system
  • The potential applications and advantages of organoids in the fields of Immuno-Oncology and anti-cancer therapeutics

Who should attend?

  • Academic researchers
  • Pharma researchers
  • Cancer researchers
  • Researchers with interest in 3D cell culture
     

Speakers

Dr. Samantha Nicholson

Dr. Samantha Nicholson

MilliporeSigma

Technical Marketing Manager, Cell Culture Workflow

Dr. Samantha Nicholson completed her PhD in Biochemistry at the University of Cape Town in 2012 and went on to complete two postdoctoral fellowships centred around the application of genome engineering technologies (CRISPR/ZFN and TALEN) to treat infectious diseases such as HIV and HBV. These experiences provided Dr. Nicholson with just over a decade of expertise in both cell and molecular biology, whereafter she joined MilliporeSigma as a technical specialist for Africa and the Middle East. In this role she focused on advanced genomics, molecular biology, and cell culture, and helped clients develop novel protocols and assays, while supporting the technical adoption of several cutting-edge technologies including CRISPR-Cas9 and siRNA. Following the success if these projects Dr. Nicholson was promoted to the position of Global Technical Application and Process Improvement Specialist for genome engineering, where she continued to drive the adoption of CRISPR technologies and advanced modelling at a global scale. Dr. Nicholson has since transitioned into her current role as Global Technical Marketing Manager for Cell Culture Workflows, where she focuses on supporting the growth and adoption of advanced modelling and cell culture techniques to create better disease models, advance drug discovery, and develop more precise and effective cell-based therapies.

Eider Valle-Encinas

Eider Valle-Encinas

Scientific Business Development Manager, The Hub Organoids

PhD

Dr. Eider Valle-Encinas is a Scientific Business Developer Manager at HUB Organoids. She obtained her PhD at Cardiff University where and holds over 7 years of experience with organoid-technology in diverse institutions such as the Netherlands Cancer Institute, the Massachusetts Institute of Technology (MIT) and the Beatson Institute. In her current role, she provides scientific guidance to HUB costumers and operates as a liaison between Sales, Marketing and the Research Team of HUB Organoids.

Carolina Sierra

Carolina Sierra

MilliporeSigma

Scientist Cell Biology

Carolina Sierra is a scientist in the Cell Biology R&D department at MilliporeSigma in Southern California. Her current role includes the evaluation and development of advanced cell culture products with emphasis on patient derived 3D organoid cultures. She obtained her B Sc. degree in Bacteriology from Javeriana University in Bogota, Colombia. Carolina also received a PhD in Microbiology and Immunology from University of Texas Medical Branch studying Type III Secretion System bacterial effectors. After graduation she joined the Gastroenterology Division at Vanderbilt University Medical Center initially as a Postdoctoral Fellow and then became faculty. At Vanderbilt her research was focused on H. pylori induced inflammation and gastric carcinogenesis, as well as the use of patient derived organoids as models to study host-pathogen interactions and novel chemopreventive strategies for gastric adenocarcinoma.

Alli Lynch

Alli Lynch

MilliporeSigma

Scientist III Applications & Manufacturing Support

Alli Lynch is a R&D Scientist working in the Applications Development group within MilliporeSigma. She received her PhD in Molecular Microbiology from University College Cork in 2018, where her research involved the genetic characterization of the role of glycine lipids in Bacteroides, a major member of the human gut microbiome. Alli joined in 2019, working on applications development of cell culture tools within the MilliporeSigma portfolio.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?